Expanded Access to Amicus Investigational Drugs

Expanded Access Program (EAP)

Since the company’s earliest days, extraordinary dedication to people affected by rare and orphan diseases has been a hallmark of Amicus Therapeutics. Our mission is to develop new medicines that improve the health and well-being of people living with rare diseases. With the development of medicines designed to satisfy unmet medical needs, comes the promise that these medicines will be broadly accessible.

Click on the link in the right-hand navigation panel to access our EAP policy. Amicus will periodically review the Expanded Access Program policy and reserves the right to modify the policy or change or discontinue the program at any time.

Physicians or qualified healthcare providers (HCP) may submit a request by completing the following intake forms:

Resources & Downloads

Key Amicus Contacts

Expanded Access to investigational drugs

Update on ongoing clinical studies 

Pompe Access Programs

More information about Expanded Access Programs